Cns Pharmaceuticalsincis A Clinical Stage Biotechnology Company Based In Houstontexasfocused On Developing Innovative Therapies For Brain And Central Nervous System Cancersparticularly Glioblastoma Multiformegbm Founded In 2017The Company Is Publicly Traded On Nasdaq Under The Ticker Symbol Cnspwith A Small Teamcns Pharmaceuticals Is Dedicated To Overcoming Challenges In Treating Cns Malignanciesespecially The Blood Brain Barrier The Company S Lead Drug Candidateberubicinis Designed To Cross The Blood Brain Barrier And Has Completed Phase I Trials For Gbmadditionallycns Pharmaceuticals Is Advancing Tpi 287A Microtubule Inhibitor That Shows Promise In Treating Cns Tumorsthe Company Engages In Clinical Trial Management And Collaborates With Institutions Like Md Anderson Cancer Center And Reata Pharmaceuticals To Enhance Its Drug Development Effortscns Pharmaceuticals Aims To Address Unmet Medical Needs In Neuro Oncologyprimarily Serving Patients With Brain Cancers Through Its Clinical Trials
